Cambridge Investment Research Advisors
INSY

Cambridge Investment Research Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Cambridge Investment Research Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,174
Closed -$107K – 2271
2017
Q4 		$107K Sell
11,174
-29,220
-72% -$191K ﹤0.01% 2021
2017
Q3 		$359K Buy
40,394
+2,509
+7% +$25.9K ﹤0.01% 1451
2017
Q2 		$479K Buy
37,885
+1,541
+4% +$18.2K 0.01% 1225
2017
Q1 		$382K Buy
+36,344
New +$387K 0.01% 1219

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cambridge Investment Research Advisors's INSY Position: Q1 2018 in Review

Cambridge Investment Research Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 11,174 shares — an estimated $107K sold.

Cambridge Investment Research Advisors first reported a position in INSY in Q1 2017 and held it in 4 quarters. The position peaked at $479K in Q2 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Cambridge Investment Research Advisors reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 11,174 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $107K.
  • Cambridge Investment Research Advisors first reported a position in Insys Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Insys Therapeutics, Inc. position peaked at $479K in Q2 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2018, filed 9 May 2018.